Spots Global Cancer Trial Database for Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

Official Title: An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix

Study ID: NCT02492503

Conditions

Metastatic Carcinoma to the Uterine Cervix

Recurrent Carcinoma Cervix

Cervix Carcinoma Recurrent

Interventions

Paclitaxel and carboplatin

Study Description

Brief Summary: Experience with substituting carboplatin for cisplatin is limited in advanced and recurrent cervix cancer and there has been no counterpart to GOG 158, which documented therapeutic equivalency of cisplatin/paclitaxel and carboplatin/paclitaxel for treatment of ovarian cancer, performed in a cervix cancer population.

Detailed Description: This trial will be a prospective, randomized phase II pilot study. Consecutive patients of metastatic, recurrent or refractory carcinoma cervix enrolled in gynecology clinic at IRCH, AIIMS will be taken into study after taking informed consent. Patients will be randomized into two arms. Each arm shall contain 20 patients. The patients shall receive paclitaxel and carboplatin q3wk in first arm and paclitaxel and carboplatin q1 wk in second arm.